EUVIMEDEUVIMED entdecken
Crossref

Endothelial-to-mesenchymal transition primes vascular endothelial cells toward an osteochondrogenic fate

Franceska Kishta, Ignacio Fernando Hall, Guanliang Li, Tanushree Tripathi, Matthieu Vermeren, Justyna Cholewa-Waclaw, Fiona Rossi, Bruno M Péault, Julie Rodor, Abdelaziz Beqqali, Judith C Sluimer, Mihaela Crisan und 1 weitere

Vascular Pharmacology · 2026-03 · 162 · 107579

DOI: 10.1016/j.vph.2025.107579 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vascular Pharmacology, 2026-03. Verfasst von Franceska Kishta und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Neuroscience and Cardiovascular Research, University of Edinburgh, Edinburgh EH16 4TJ, UK. Hauptthemen laut MEDLINE: Human Umbilical Vein Endothelial Cells, Osteogenesis, Mesenchymal Stem Cells, Chondrogenesis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 67 Literaturangaben. Gefördert von: European Research Council, British Heart Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Endothelial-to-mesenchymal transition (EndMT), in which endothelial cells (ECs) lose their endothelial identity and acquire mesenchymal-like features, contributes to vascular dysfunction and remodeling in atherosclerosis. However, the fate and function of these cells remain unclear. Here, we investigated their differentiation potential and functional properties to define how EndMT contributes to vascular dysfunction. Human umbilical vein ECs (HUVECs) were treated with transforming growth factor-β2 (TGF-β2) and interleukin-1β (IL-1β) for seven days to induce EndMT. Mesenchymal stem/stromal cell (MSC) identity was assessed by flow cytometry for canonical markers (CD44, CD73, CD105, CD90). Differentiation states were evaluated using published single-cell RNA sequencing (scRNA-seq) data of EndMT-treated HUVECs and validated under lineage-specific culture environments. In vivo analysis was performed using scRNA-seq data from EC lineage reporter mice in atherosclerosis models. EndMT-treated HUVECs displayed an intermediate mesenchymal phenotype, expressing CD44, CD73 and CD105 but lacking CD90, failing to meet MSC criteria. Potency analysis showed that 77 % of EndMT-treated HUVECs remained oligopotent, while 19 % acquired osteogenic and chondrogenic potential, accompanied by activation of lineage-associated transcriptional programs (RUNX2, BMPR1A, NOTCH2, WNT5A; CD151, ANXA6, DCN). In vivo, endothelial lineage-traced cells in atherosclerotic mice formed an EndMT cluster enriched for osteogenic and chondrogenic gene programs, including ossification and cartilage development pathways. We define a primed oligopotent state of EndMT-derived cells both in vitro and in vivo, marked by transition toward osteogenic and chondrogenic fates. These findings suggest that EndMT contributes to atherosclerosis by generating osteogenic- and chondrogenic-like cells, linking endothelial dysfunction to vascular calcification in disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Human Umbilical Vein Endothelial CellsOsteogenesisMesenchymal Stem CellsChondrogenesisAtherosclerosisVascular CalcificationAortic DiseasesAnimalsHumansDisease Models, AnimalCells, CulturedCell DifferentiationMice, Inbred C57BLCell LineagePhenotypeMiceMaleEndoglinSignal Transduction

Stichwörter der Autor:innen

AtherosclerosisChondrogenic differentiationEndothelial-to mesenchymal transition (EndMT)Osteogenic differentiationTherapeutic targetingVascular calcificationVascular dysfunction

Substanzen

Endoglin

Autor:innen und Institutionen

  • Institute for Neuroscience and Cardiovascular Research, University of Edinburgh, Edinburgh EH16 4TJ, UK.
  • Department of Pathology, CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht 6229ER, the Netherlands.
  • Center for Regenerative Medicine, Institute for Regeneration and Repair, University of Edinburgh, Edinburgh EH16 4UU, UK.
  • Institute for Neuroscience and Cardiovascular Research, University of Edinburgh, Edinburgh EH16 4TJ, UK; Department of Orthopedic Surgery and Orthopedic Hospital Research Center, University of California, Los Angeles, C…
  • Institute for Neuroscience and Cardiovascular Research, University of Edinburgh, Edinburgh EH16 4TJ, UK; Department of Pathology, CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht 6229ER, the N…
  • Institute for Neuroscience and Cardiovascular Research, University of Edinburgh, Edinburgh EH16 4TJ, UK; Center for Regenerative Medicine, Institute for Regeneration and Repair, University of Edinburgh, Edinburgh EH16 4…

Förderung

  • European Research Council
  • British Heart Foundation

Zitieren

APA

Kishta, F., Hall, I. F., Li, G., Tripathi, T., Vermeren, M., Cholewa-Waclaw, J., Rossi, F., Péault, B. M., Rodor, J., Beqqali, A., Sluimer, J. C., Crisan, M., & Baker, A. H. (2026). Endothelial-to-mesenchymal transition primes vascular endothelial cells toward an osteochondrogenic fate. Vascular Pharmacology, 162, 107579. https://doi.org/10.1016/j.vph.2025.107579

Vancouver

Kishta F, Hall IF, Li G, Tripathi T, Vermeren M, Cholewa-Waclaw J, et al. Endothelial-to-mesenchymal transition primes vascular endothelial cells toward an osteochondrogenic fate. Vascular Pharmacology. 2026;162:107579. doi:10.1016/j.vph.2025.107579

BibTeX
@article{Kishta2026,
  author = {Kishta, Franceska and Hall, Ignacio Fernando and Li, Guanliang and Tripathi, Tanushree and Vermeren, Matthieu and Cholewa-Waclaw, Justyna and Rossi, Fiona and Péault, Bruno M and Rodor, Julie and Beqqali, Abdelaziz and Sluimer, Judith C and Crisan, Mihaela and Baker, Andrew H},
  title = {Endothelial-to-mesenchymal transition primes vascular endothelial cells toward an osteochondrogenic fate},
  journal = {Vascular Pharmacology},
  year = {2026},
  volume = {162},
  pages = {107579},
  doi = {10.1016/j.vph.2025.107579}
}
Kostenlos starten →